ANIP Form 144: 91,000 Shares Proposed Sale Worth $7.87M

ANI Pharmaceuticals (ANIP) filed a Form 144 proposing the sale of 91,000 common shares.

Rhea-AI Filing Summary

ANI Pharmaceuticals (ANIP) filed a Form 144 proposing the sale of 91,000 common shares. The shares are scheduled for an approximate sale date of 08/15/2025 through Morgan Stanley Smith Barney LLC and carry an aggregate market value of $7,866,267.50. The filing reports 21,688,772 shares outstanding, meaning the proposed sale represents a small fraction of total shares. The 91,000 shares were acquired on 11/19/2021 in exchange for convertible preferred shares and were paid for in cash on the acquisition date. No other sales in the prior three months were reported.

Positive

• Clear compliance disclosure: The filer provides required Rule 144 details including broker, acquisition date, basis of acquisition, aggregate market value, and approximate sale date.

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider plans to sell 91,000 ANIP shares (~$7.87M) acquired via convertible preferreds in 2021; filing follows Rule 144 disclosure requirements.

The Form 144 discloses a proposed sale executed through Morgan Stanley Smith Barney LLC with an approximate sale date of 08/15/2025. The position was originally acquired on 11/19/2021 via convertible preferred shares and paid in cash, which is relevant for determining resale eligibility under Rule 144. The disclosed aggregate market value ($7.87M) and the stated shares outstanding (21,688,772) allow market participants to gauge the sale's relative size; the sale represents a modest percentage of outstanding shares.

Corporate Governance Expert

TL;DR: The filer provided required attestation and signature language; no undisclosed material information is claimed.

The filing includes the standard attestation that the seller is not aware of any undisclosed material adverse information about the issuer and notes the Rule 10b5-1 trading plan language if applicable. The submission identifies the broker and confirms there were no related sales in the prior three months. From a governance and disclosure standpoint, the filing appears procedurally complete for a Rule 144 notice.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does ANIP's Form 144 disclose about the proposed sale?

The Form 144 discloses a proposed sale of 91,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $7,866,267.50 and approximate sale date of 08/15/2025.

How and when were the 91,000 ANIP shares acquired?

The shares were acquired on 11/19/2021 through a conversion of convertible preferred shares, with payment noted as cash on the acquisition date.

How large is the proposed sale relative to ANIP's outstanding shares?

The filing reports 21,688,772 shares outstanding, so the 91,000-share sale represents a small percentage of total shares outstanding.

Were there any other sales by this person in the past three months?

The Form 144 indicates Nothing to Report for securities sold during the past three months.

Which broker is handling the proposed ANIP sale?

The proposed sale is to be executed through Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/15/2025 - 04:26 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001806621
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ANI Pharmaceuticals, Inc.
SEC File Number	001-31812
Address of Issuer	210 Main Street West Baudette MINNESOTA 56623
Phone	(218) 634-3500
Name of Person for Whose Account the Securities are To Be Sold	AMPERSAND 2020 LIMITED PARTNERSHIP
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	91000	7866267.50	21688772	08/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/19/2021	Convertible Preferred Shares	Issuer			91000	11/19/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/15/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Dana L Niles
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)